Apoptosis: target for novel drugs

被引：38

作者：

Alam, JJ ^{[1
]}

机构：

[1] Vertex Pharmaceut, Cambridge, MA 02139 USA

来源：

TRENDS IN BIOTECHNOLOGY | 2003年 / 21卷 / 11期

关键词：

D O I：

10.1016/j.tibtech.2003.08.006

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Targeting apoptotic cell death pathways provides wide-ranging opportunities for the discovery and development of novel drugs. Some targeted therapies that selectively induce apoptosis in cancer cells are already marketed, and numerous pro-apoptotic drugs for treating cancer are currently being developed. The antiapoptotic drugs that are most advanced in development are targeting acute disease indications such as stroke, myocardial infarction and sepsis, in which the role of apoptosis has been best defined and inhibitors of the apoptotic pathway have shown activity in various animal models. In the future, novel drugs might also result from an understanding of apoptotic pathways in chronic disorders.

引用

页码：479 / 483

页数：5

共 57 条

[1] Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure [J].

Abbate, A ;

Biondi-Zoccai, GGL ;

Bussani, R ;

Dobrina, A ;

Camilot, D ;

Feroce, F ;

Rossiello, R ;

Baldi, F ;

Silvestri, F ;

Biasucci, LM ;

Baldi, A .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (05) :753-760

[2]

Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574

[3]

Bilsland James, 2002, Curr Opin Investig Drugs, V3, P1745

[4] Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury [J].

Brines, ML ;

Ghezzi, P ;

Keenan, S ;

Agnello, D ;

de Lanerolle, NC ;

Cerami, C ;

Itri, LM ;

Cerami, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10526-10531

[5] Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury [J].

Celik, M ;

Gökmen, N ;

Erbayraktar, S ;

Akhisaroglu, M ;

Konakç, S ;

Ulukus, C ;

Genc, S ;

Genc, K ;

Sagiroglu, E ;

Cerami, A ;

Brines, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) :2258-2263

[6] A Novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin reduces myocardial ischemic injury [J].

Chapman, JG ;

Magee, WP ;

Stukenbrok, HA ;

Beckius, GE ;

Milici, AJ ;

Tracey, WR .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 456 (1-3) :59-68

[7] Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists [J].

Chen, YNP ;

Sharma, SK ;

Ramsey, TM ;

Jiang, L ;

Martin, MS ;

Baker, K ;

Adams, PD ;

Bair, KW ;

Kaelin, WG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4325-4329

[8] Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis [J].

Chung, CS ;

Yang, S ;

Song, GY ;

Lomas, J ;

Wang, P ;

Simms, HH ;

Chaudry, IH ;

Ayala, A .

SURGERY, 2001, 130 (02) :339-345

[9]

Ciardiello F, 2000, CLIN CANCER RES, V6, P2053

[10] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

← 1 2 3 4 5 6 →